Allt inom mfn_news

Nanexa AB (publ) announced today that the company is entering an intensive period of international presence, with a particular focus on NEX-22 – the company’s long-acting formulation of liraglutide based on the PharmaShell® platform – featuring new data from its proprietary drug delivery technology.

Nanexa announced today that all pharmacokinetic (PK) samples from the final dose group, 30 mg of the Phase I study for NEX-22, now have been analyzed. The results show increased exposure in line with the dose escalation and further demonstrate a controlled and prolonged release of liraglutide, which supports a one-month depot of liraglutide.